

CORRECTION

Open Access



Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Samuel A. Jacobs^{1*}, Ying Wang¹, Jame Abraham^{1,2}, Huichen Feng¹, Alberto J. Montero^{1,2,3}, Corey Lipchik¹, Melanie Finnigan¹, Rachel C. Jankowitz^{1,4,5}, Mohamad A. Salkeni^{1,6,7}, Sai K. Maley¹, Shannon L. Puhalla^{1,8,9}, Fanny Piette¹⁰, Katie Quinn¹¹, Kyle Chang¹¹, Rebecca J. Nagy¹¹, Carmen J. Allegra^{1,12}, Kelly Vehec¹, Norman Wolmark^{1,8}, Peter C. Lucas^{1,8,9,13}, Ashok Srinivasan^{1,14} and Katherine L. Pogue-Geile¹

Correction: Jacobs et al. *Breast Cancer Research* (2024) 26:69.

<https://doi.org/10.1186/s13058-024-01823-8>.

Following the publication of the original article, there were several errors, as follows:

In the abstract, Results section, “95% CI” should be included in the sixth sentence. It should read: “Molecular

Response scores were significantly associated with both PFS (HR 0.28, 95% CI 0.09-0.90, $P = 0.033$) and best response ($P = 0.037$).”

On page 4, left-hand column: The word “samples,” after the word “two,” was mistakenly removed during typesetting. The correct statement should have been “... the percent ctDNA change between the two timepoints based on the mean variant allele frequency (VAF) between two samples (mean VAF_2 /mean VAF_1) - 1 \times 100%.”

On page 7, left-hand column, a statement of “0.09-0.90, $P = 0.033$ using Wilcox test” was duplicated and has been removed.

The original article has been corrected.

Published online: 24 May 2024

The online version of the original article can be found at <https://doi.org/10.1186/s13058-024-01823-8>.

*Correspondence:

Samuel A. Jacobs
jacobssa1945@gmail.com

¹NSABP Foundation, Pittsburgh, PA, USA

²Cleveland Clinic, Taussig Cancer Institute, Weston, Cleveland, OH, USA

³University Hospitals/Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA

⁴University of Pittsburgh, Pittsburgh, PA, USA

⁵Present address: University of Pennsylvania Perelman School of Medicine, State College, Philadelphia, PA, USA

⁶National Institutes of Health, Washington, DC, USA

⁷Present address: Virginia Cancer Specialists, Fairfax, VA, USA

⁸UPMC Hillman Cancer Center, Pittsburgh, PA, USA

⁹University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

¹⁰International Drug Development Institute, Louvain-la-Neuve, Belgium

¹¹Guardant Health, Redwood City, CA, USA

¹²University of Florida Health, Gainesville, FL, USA

¹³Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

¹⁴Autism Impact Fund, Pittsburgh, PA, USA

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.